TITLE

Review: Erythropoiesis-stimulating agents increase mortality in patients with cancer

AUTHOR(S)
Matulonis, Ursula; Engert, A.
PUB. DATE
September 2009
SOURCE
ACP Journal Club;9/22/2009, Vol. 151 Issue 3, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the findings of a study to assess whether erythropoiesis-stimulating agents (ESAs) used for prevention or treatment of anemia increase mortality in patients with cancer. Studies included a comparison between ESAs plus red blood cell (RBC) transfusions and RBC transfusion alone for treatment of anemia. The study revealed that ESAs increase mortality in patients who have cancer and anemia or potential for anemia.
ACCESSION #
44638104

 

Related Articles

  • Kosten der Verabreichung von Blutkonserven im Krankenhaus. Hönemann, C.; Bierbaum, M.; Heidler, J.; Doll, D.; Schöffski, O. // Der Chirurg;May2013, Vol. 84 Issue 5, p426 

    Introduction: In clinical practice there are medical and economic reasons against the thoughtless use of packed red blood cells (rbc). Therefore, in searching for alternatives (therapy of anemia) the total costs of allogeneic blood transfusions must be considered. Using a practical example this...

  • Alternate Night NHHD Found to Improve Anemia.  // Renal & Urology News;Nov2014, Vol. 13 Issue 11, p15 

    The article presents research indicating the significance of nocturnal home hemodialysis on alternate nights in improving anemia and in decreasing the use of erythropoiesis-stimulating agent.

  • ESAs associated with increased mortality risk, not recommended for routine treatment.  // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p47 

    The article discusses research on the association of erythropoiesis-stimulating agents (ESS) with increased risk of death in patients with cancer-specific anemia, that references a study by M. Tonelli published in a 2009 issue of the "Canadian Medical Association Journal."

  • Reduction in Red Blood Cell Transfusions Using a Bedside Analyzer in Extremely Low Birth Weight Infants. Madan, Ashima; Kumar, Rahi; Adams, Marian M; Benitz, William E; Geaghan, Sharon M; Widness, John A // Journal of Perinatology;Jan2005, Vol. 25 Issue 1, p21 

    BACKGROUND:: Preterm infants typically experience heavy phlebotomy losses from frequent laboratory testing in the first few weeks of life. This results in anemia, requiring red blood cell (RBC) transfusions. We recently introduced a bedside point-of-care (POC) blood gas analyzer (iSTAT,...

  • An assessment of iron overload in children treated for cancer and nonmalignant hematologic disorders. Rascon, Jelena; Rageliene, Lina; Stankeviciene, Sigita; Palionis, Darius; Tamosiunas, Algirdas; Valeviciene, Nomeda; Zvirblis, Tadas // European Journal of Pediatrics;Sep2014, Vol. 173 Issue 9, p1137 

    Our goal was to assess the natural fate of iron overload (IO) following transfusions of packed red blood cells (PRBCs) in children treated for cancer and nonmalignant disorders according to the intensity level of their treatment. Sixty-six children were followed up from February 2010 to March...

  • Anemia Treatment Through the Years. Szromba, Charlotte // Nephrology Nursing Journal;Mar/Apr2009, Vol. 36 Issue 2, p229 

    The article presents an answer to a question about the type of treatment available to anemia patients before treatment with erythropoiesis-stimulating agents (ESA) was available to them.

  • Twilight of ESA Monopoly as New Anemia Options Advance. Morrison, Trista // BioWorld Insight;12/19/2011, Vol. 19 Issue 51, p1 

    The article reports on the trends in the erythropoiesis-stimulating agents (ESA) market in the U.S. The author mentions that there will be changes in the market as advanced anemia treatment options are emerging in the country. She adds that changes are evident in the field chemotherapy-induced...

  • Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. MOUNTZIOS, GIANNIS; ARAVANTINOS, GERASIMOS; ALEXOPOULOU, ZOI; TIMOTHEADOU, ELENI; MATSIAKOU, FOTINI; CHRISTODOULOU, CHRISTOS; LASCHOS, KONSTANTINOS; GALANI, ELENI; KOUTRAS, ANGELOS; BAFALOUKOS, DIMITRIOS; LINARDOU, HELENA; PECTASIDES, DIMITRIOS; VARTHALITIS, IOANNIS; PAPAKOSTAS, PAVLOS; KALOFONOS, HARALAMBOS P.; FOUNTZILAS, GEORGE // Molecular & Clinical Oncology;Feb2016, Vol. 4 Issue 2, p211 

    Prophylactic erythropoiesis-stimulating agent (ESA) administration for chemotherapy-induced anemia (CIA) is not supported by current guidelines. Long-term follow-up of patients who had been treated with ESA for CIA in the past may provide useful information. In 2002, we undertook a prospective,...

  • Use of erythropoietin-stimulating agents in breast cancer patients: A risk review. Crouch, Zachary; Hermes DeSantis, Evelyn R. // American Journal of Health-System Pharmacy;7/1/2009, Vol. 66 Issue 13, p1180 

    Purpose. The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. Summary. Before the introduction of ESAs, the only treatment option for cancerrelated anemia was red blood cell (RBC) transfusion. The use of ESAs in multiple disease states has been well...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics